Martina Sterneck

Martina Sterneck

Auto-generated profile, based on publicly available information

Martina Sterneck

I. Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2017 in Transplant International
Verified
Journal Article
Closed access
PDF file
HAHilke Andresen-Streichert
Hilke Andresen-Streichert
YBYannick Beres
Yannick Beres
WWWolfgang Weinmann
Wolfgang Weinmann
ASAlexandra Schröck
Alexandra Schröck
AMAlexander Müller
Alexander Müller
MSMartina Sterneck
Martina Sterneck
Phosphatidylethanol (PEth) is a new, highly specific alcohol marker. The aim of this study was to assess its diagnostic value in the liver transplant setting. In 51 pre‐ and 61 post‐transplant patients with underlying alcoholic liver disease PEth, ethanol, methanol, carbohydrate‐deficient transferrin (CDT), and ethyl glucuronide in urine (uEtG) and hair (hEtG) were tested and compared with patients’ questionnaire reports. Twenty‐eight (25%) patients tested positive for at least one alcohol marker. PEth alone revealed alcohol consumption in 18% of patients. With respect to detection of alcohol intake in the preceding week, PEth showed a 100% sensitivity. PEth testing was more sensitive than the determination of ethanol, methanol, CDT or uEtG alone [sensitivity 25% (confidence interval (CI) 95%, 7–52%), 25% (7–52%), 21% (6–45%) and 71% (41–91%), respectively], or ethanol, methanol and uEtG taken in combination with 73% (45–92%). Specificity of all markers was 92% or higher. Additional testing of hEtG revealed alcohol consumption in seven patients, not being positive for any other marker. Phosphatidylethanol was a highly specific and sensitive marker for detection of recent alcohol consumption in pre‐ and post‐transplant patients. The additional determination of hEtG was useful in disclosing alcohol consumption 3–6 months retrospectively.

16 June 2013 in Liver International
Verified
Journal Article
Closed access
PDF file
MSMartina Sterneck
Martina Sterneck
MYMichel Yegles
Michel Yegles
GVGregor Rothkirch von
Gregor Rothkirch von
KSKatharina Staufer
Katharina Staufer
EVEik Vettorazzi
Eik Vettorazzi
HAHilke Andresen‐Streichert
Hilke Andresen‐Streichert

10 May 2016 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
MSMartina Sterneck
Martina Sterneck
GKGernot M. Kaiser
Gernot M. Kaiser
NHNils Heyne
Nils Heyne
NRNicolas Richter
Nicolas Richter
FRFalk Rauchfuss
Falk Rauchfuss
HSHans J. Schlitt
Hans J. Schlitt

Verified
Journal Article
Open access
PDF file
TBThomas Theo Brehm
Thomas Theo Brehm
AHAndreas Heyer
Andreas Heyer
KRKevin Roedl
Kevin Roedl
DJDominik Jarczak
Dominik Jarczak
ANAxel Nierhaus
Axel Nierhaus
JWJulian Schulze zur Wiesch
Julian Schulze zur Wiesch
In this study, we directly compared coronavirus disease 2019 (COVID-19) patients hospitalized during the first (27 February–28 July 2020) and second (29 July–31 December 2020) wave of the pandemic at a large tertiary center in northern Germany. Patients who presented during the first (n = 174) and second (n = 331) wave did not differ in age (median [IQR], 59 years [46, 71] vs. 58 years [42, 73]; p = 0.82) or age-adjusted Charlson Comorbidity Index (median [IQR], 2 [1, 4] vs. 2 [0, 4]; p = 0.50). During the second wave, a higher proportion of patients were treated as outpatients (11% [n = 20] vs. 20% [n = 67]), fewer patients were admitted to the intensive care unit (43% [n = 75] vs. 29% [n = 96]), and duration of hospitalization was significantly shorter (median days [IQR], 14 [8, 34] vs. 11 [5, 19]; p < 0.001). However, in-hospital mortality was high throughout the pandemic and did not differ between the two periods (16% [n = 27] vs. 16% [n = 54]; p = 0.89). While novel treatment strategies and increased knowledge about the clinical management of COVID-19 may have resulted in a less severe disease course in some patients, in-hospital mortality remained unaltered at a high level. These findings highlight the unabated need for efforts to hamper severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) transmission, to increase vaccination coverage, and to develop novel treatment strategies to prevent mortality and decrease morbidity.

1 January 2017 in World Journal of Hepatology
Verified
Journal Article
Open access
SPSven Pischke
Sven Pischke
MLMarie C Lege
Marie C Lege
MWMoritz von Wulffen
Moritz von Wulffen
AGAntonio Galante
Antonio Galante
BOBenjamin Otto
Benjamin Otto
MSMartina Sterneck
Martina Sterneck
To identify predictive factors associated with long-term patient and graft survival (> 15 years) in liver transplant recipients. Medical charts of all de novo adult liver transplant recipients (n = 140) who were transplanted in Hamburg between 1997 and 1999 were retrospectively reviewed. In total, 155 transplantations were identified in this time period (15 re-transplantations). Twenty-six orthotopic liver transplant (OLT) recipients were early lost to follow-up due to moving to other places within 1 year after transplantation. All remaining 114 patients were included in the analysis. The following recipient factors were analysed: Age, sex, underlying liver disease, pre-OLT body mass index (BMI), and levels of alanine aminotransferase (ALT), bilirubin, creatinine and gamma-glutamyltransferase (gamma-GT), as well as warm and cold ischemia times. Furthermore, the following donor factors were assessed: Age, BMI, cold ischemia time and warm ischemia time. All surviving patients were followed until December 2014. We divided patients into groups according to their underlying diagnosis: (1) hepatocellular carcinoma (n = 5, 4%); (2) alcohol toxic liver disease (n = 25, 22.0%); (3) primary sclerosing cholangitis (n = 6, 5%); (4) autoimmune liver diseases (n = 7, 6%); (5) hepatitis C virus cirrhosis (n = 15, 13%); (6) hepatitis B virus cirrhosis (n = 21, 19%); and (7) other (n = 35, 31%). The group “other” included rare diagnoses, such as acute liver failure, unknown liver failure, stenosis and thrombosis of the arteria hepatica, polycystic liver disease, Morbus Osler and Caroli disease. The majority of patients were male (n = 70, 61%). Age and BMI at the time point of transplantation ranged from 16 years to 69 years (median: 53 years) and from 15 kg/m2 to 33 kg/m2 (median: 24), respectively. Sixty-six OLT recipients (58%) experienced a follow-up of 15 years after transplantation. Recipient’s age (P = 0.009) and BMI (P = 0.029) were identified as risk factors for death by χ2-test. Kaplan-Meier analysis confirmed BMI or age above the median as predictors of decreased long-term survival (P = 0.008 and P = 0.020). Hepatitis B as underlying disease showed a trend for improved long-term survival (P = 0.049, χ2-test, P = 0.055; Kaplan-Meier analysis, Log rank). Pre-transplant bilirubin, creatinine, ALT and gamma-GT levels were not associated with survival in these patients of the pre-era of the model of end stage liver disease. The recipients’ age and BMI were predictors of long-term survival after OLT, as well as hepatitis B as underlying disease. In contrast, donors’ age and BMI were not associated with decreased survival. These findings indicate that recipient factors especially have a high impact on long-term outcome after liver transplantation.

5 May 2014 in BMC Gastroenterology
Verified
Journal Article
Open access
PDF file
MWMalte Wehmeyer
Malte Wehmeyer
FEFriederike Eißing
Friederike Eißing
SJSabine Jordan
Sabine Jordan
CRClaudia Röder
Claudia Röder
AHAnnette Hennigs
Annette Hennigs
SLStefan Lüth
Stefan Lüth
The combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of patients infected with HCV genotype 1 has led to significantly increased rates of sustained virological response (SVR) in phase III trials. There is only limited data regarding the safety and efficacy in a “real-life” cohort.